If you have been reading about Lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-07-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Organisms vary in their ability to synthesize the 20 common amino acids. Most bacteria and plants can synthesize all twenty, but mammals can only synthesize eleven nonessential amino acids, so nine essential amino acids must be obtained from food. Some simple parasites, such as the bacteria Mycoplasma pneumoniae, lack all amino acid synthesis and take their amino acids directly from their hosts. All amino acids are synthesized from intermediates in glycolysis, the citric acid cycle, or the pentose phosphate pathway. Nitrogen is provided by glutamate and glutamine. Nonessential amino acid synthesis depends on the formation of the appropriate alpha-keto acid, which is then transaminated to form an amino acid. Amino acids are made into proteins by being joined in a chain of peptide bonds. Each different protein has a unique sequence of amino acid residues: this is its primary structure. Just as the letters of the alphabet can be combined to form an almost endless variety of words, amino acids can be linked in varying sequences to form a huge variety of proteins. Proteins are made from amino acids that have been activated by attachment to a transfer RNA molecule through an ester bond. This aminoacyl-tRNA precursor is produced in an ATP-dependent reaction carried out by an aminoacyl tRNA synthetase. This aminoacyl-tRNA is then a substrate for the ribosome, which joins the amino acid onto the elongating protein chain, using the sequence information in a messenger RNA.
Multiple epiphyseal dysplasia (MED), also known as Fairbank's disease, is a rare genetic disorder (dominant form: 1 in 10,000 births) that affects the growing ends of bones. Long bones normally elongate by expansion of cartilage in the growth plate (epiphyseal plate) near their ends. As it expands outward from the growth plate, the cartilage mineralizes and hardens to become bone (ossification). In MED, this process is defective.
== Non-human infections == Streptococcus agalactiae was historically studied as a disease of cattle that harmed milk production, leading to its name "agalactiae" which means "absence of milk". Strains of bovine and human bacteria are generally interchangeable, with evidence of transmission from animals to humans and vice versa.
==== Educator tax deduction ==== Previously, educators could take a tax deduction for unreimbursed education costs of up to $300 per year (or $600 if married filing jointly) without itemizing their tax deductions. Effective January 1, 2026, eligible educators may also take an itemized tax deduction for unreimbursed education costs in excess of $300 per year (or $600 if married filing jointly). In order to qualify, the individual must work at any K–12 school for least 900 hours during the school year as a teacher, instructor, counselor, principal, aide, interscholastic sports coach, or sports administrator. The unreimbursed education costs must be directly related to the individual's work as an educator. Eligible unreimbursed education costs include books, supplies, other classroom materials, equipment, professional development courses or training that is related to the curriculum or student instruction.
Sources: en.wikipedia.org
=== Cell signalling === Citicoline may enhance cellular communication by increasing levels of neurotransmitters. The choline component of citicoline is used to create acetylcholine, which is a neurotransmitter in the human brain. Clinical trials have found that citicoline supplementation might improve focus and attention.
As of 2013, 19,400 people inhabited the Kuril Islands, of which 16,700 lived on the four disputed southern islands and 2,600 lived on Paramushir, the northernmost large island; the islands in between are uninhabited. These include ethnic Russians, Ukrainians, Belarusians, Tatars, Nivkhs, Oroch, Japanese and Ainus. Russian Orthodox Christianity is the main religion. Some of the villages are permanently occupied by Russian soldiers. Others are inhabited by civilians, who are mostly fishermen, workers in fish factories, dockers, and social sphere workers (police, medics, teachers, etc.). Construction works on the islands have attracted migrant workers from the rest of Russia and other post-Soviet states. As of 2014, there were only 8 inhabited islands out of a total of 56.
G-protein-coupled receptor oligomerisation is a widespread phenomenon. One of the best-studied examples is the metabotropic GABAB receptor. This so-called constitutive receptor is formed by heterodimerization of GABABR1 and GABABR2 subunits. Expression of the GABABR1 without the GABABR2 in heterologous systems leads to retention of the subunit in the endoplasmic reticulum. Expression of the GABABR2 subunit alone, meanwhile, leads to surface expression of the subunit, although with no functional activity (i.e., the receptor does not bind agonist and cannot initiate a response following exposure to agonist). Expression of the two subunits together leads to plasma membrane expression of functional receptor. It has been shown that GABABR2 binding to GABABR1 causes masking of a retention signal of functional receptors.
==== Neutron irradiation of uranium-235 targets ==== The parent nuclide of 99mTc, 99Mo, is mainly extracted for medical purposes from the fission products created in neutron-irradiated uranium-235 targets, the majority of which is produced in five nuclear research reactors around the world using highly enriched uranium (HEU) targets. Smaller amounts of 99Mo are produced from low-enriched uranium in at least three reactors.
Stanley Whittingham conceived intercalation electrodes in the 1970s and created the first rechargeable lithium-ion battery, based on a titanium disulfide cathode and a lithium-aluminium anode, although it suffered from safety problems and was never commercialized. John Goodenough expanded on this work in 1980 by using lithium cobalt oxide as a cathode. The first prototype of the modern Li-ion battery, which uses a carbonaceous anode rather than lithium metal, was developed by Akira Yoshino in 1985 and commercialized by a Sony and Asahi Kasei team led by Yoshio Nishi in 1991. Whittingham, Goodenough, and Yoshino were awarded the 2019 Nobel Prize in Chemistry for their contributions to the development of lithium-ion batteries. Lithium-ion batteries can be a fire or explosion hazard as they contain flammable electrolytes. Progress has been made in the development and manufacturing of safer lithium-ion batteries. Lithium-ion solid-state batteries are being developed to eliminate the flammable electrolyte. Lithium and other minerals can have significant issues in mining, with lithium being water intensive in often arid regions and other minerals used in some Li-ion chemistries potentially being conflict minerals such as cobalt. Environmental issues have encouraged some researchers to improve mineral efficiency and find alternatives such as lithium iron phosphate lithium-ion chemistries or non-lithium-based battery chemistries such as sodium-ion and iron-air batteries. Lithium-ion cells can be manufactured to optimize energy density or power density.
Sources: en.wikipedia.org
=== 3-2-1 Backup Rule === The backup data needs to be stored, requiring a backup rotation scheme, which is a system of backing up data to computer media that limits the number of backups of different dates retained separately, by appropriate re-use of the data storage media by overwriting of backups no longer needed. The scheme determines how and when each piece of removable storage is used for a backup operation and how long it is retained once it has backup data stored on it. The 3-2-1 rule can aid in the backup process. It states that there should be at least 3 copies of the data, stored on 2 different types of storage media, and one copy should be kept offsite, in a remote location (this can include cloud storage). 2 or more different media should be used to eliminate data loss due to similar reasons (for example, optical discs may tolerate being underwater while LTO tapes may not, and SSDs cannot fail due to head crashes or damaged spindle motors since they do not have any moving parts, unlike hard drives). An offsite copy protects against fire, theft of physical media (such as tapes or discs) and natural disasters like floods and earthquakes. Physically protected hard drives are an alternative to an offsite copy, but they have limitations like only being able to resist fire for a limited period of time, so an offsite copy still remains as the ideal choice. Because there is no perfect storage, many backup experts recommend maintaining a second copy on a local physical device, even if the data is also backed up offsite.
==== Sepsis ==== A variety of factors associated with sepsis may cause cholestasis. Typically, patients have conjugated hyperbilirubinemia and alkaline phosphatase (ALP) elevation but not to extreme levels. Sepsis-induced cholestasis may occur due to increased serum lipopolysaccharide levels. Lipopolysaccharides can inhibit and down-regulate bile salt transporters in hepatocytes, thereby leading to cholestasis. As such, in the case of sepsis, cholestasis occurs not as a result of impaired obstruction but rather the disruption of bile flow. Ischemic liver injury resulting from sepsis can also cause cholestasis. Importantly, jaundice is not indicative of cholestasis in all cases. Widespread hemolysis resulting from sepsis may release bilirubin, thereby overwhelming bilirubin reabsorption and excretion mechanism.
ACT-389949: A small-molecule FPR2 agonist that has completed phase 1 clinical trials BMS-986235: Another FPR2 agonist in phase 1 trials, with evidence of resolving cardiac inflammation and improving cardiac function in preclinical models. BLXA4 (Methyl ester-benzo-lipoxin A4): An LXA4 analog tested in phase 1 clinical trials for gingival inflammation, shown to reduce local inflammation. Rezuforimod is a potent and selective FPR2 agonist that inhibits neutrophil adhesion and exhibits broad anti-inflammatory activity.
D-amino-acid transaminase (EC 2.6.1.21) is an enzyme originally characterised from bacteria that catalyzes several reversible chemical reactions that interconvert specific D-amino acids and α-ketoglutaric acid with the corresponding α-keto acid and D-glutamic acid. For example, it can use D-alanine as a substrate:
Cotadutide is an experimental drug for the treatment of type 2 diabetes mellitus. It lowers blood glucose levels by mimicking the human hormones glucagon-like peptide 1 and glucagon, which play a role in blood sugar regulation. The drug is a peptide that is injected under the skin. Cotadutide is in Phase II clinical trials as of February 2021. Cotadutide, a therapeutic agent, was undergoing Phase II clinical trials. This stage of trials typically involves evaluating the drug's effectiveness and further assessing its safety in a larger group of participants, compared to earlier phases.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.